Valuation : ACLS THER

Market Cap 810M 697M 658M 599M 1.12B 77.47B 1.13B 7.83B 3.01B 39.3B 3.04B 2.98B 125B P/E 2026 *
-8.52x
P/E 2027 * -7x
Enterprise Value 657M 565M 533M 486M 908M 62.84B 916M 6.35B 2.44B 31.87B 2.47B 2.41B 101B EV / Sales 2026 *
104x
EV / Sales 2027 * 124x
Free-Float
97.82%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-01-16
President 67 2024-11-17
Director of Finance/CFO 39 2022-12-31
Director TitleAgeSince
Chairman 56 2022-12-31
Director/Board Member 50 2014-08-31
Director/Board Member 59 2016-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.21%-4.03%+30.97%+74.42% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.05%-4.43%+30.56%+10.07% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
+0.19%-3.79%+14.36%-19.64% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-1.94%-4.94%-5.29%+495.65% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -1.02%-3.30%+39.08%+171.31% 30.3B
Weighted average by Cap. -0.67%-3.10%+35.45%+136.73%

Financials

2026 *2027 *
Net sales 6.34M 5.45M 5.14M 4.69M 8.76M 606M 8.84M 61.25M 23.57M 307M 23.8M 23.28M 976M 5.34M 4.59M 4.33M 3.95M 7.38M 510M 7.44M 51.58M 19.85M 259M 20.04M 19.61M 822M
Net income -90.33M -77.68M -73.3M -66.77M -125M -8.64B -126M -873M -336M -4.38B -339M -332M -13.91B -112M -96.61M -91.15M -83.04M -155M -10.74B -157M -1.09B -418M -5.45B -422M -413M -17.3B
Net Debt -153M -132M -124M -113M -212M -14.64B -213M -1.48B -569M -7.42B -575M -562M -23.58B -147M -126M -119M -108M -203M -14.01B -204M -1.42B -545M -7.11B -550M -538M -22.57B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!